Skip to main content

Advertisement

Advertisement

Moderna expects Covid-19 vaccine trial data for children aged 2-5 in March

CAMBRIDGE, Massachusetts — Moderna said on Wednesday (Jan 12) it expects to report data from its Covid-19 vaccine trial in children aged between 2 to 5 years in March.

Moderna expects Covid-19 vaccine trial data for children aged 2-5 in March

Moderna's vaccine already has authorisations in Europe, UK, Australia, and Canada for adolescents aged 12-17 years.

CAMBRIDGE, Massachusetts — Moderna said on Wednesday (Jan 12) it expects to report data from its Covid-19 vaccine trial in children aged between 2 to 5 years in March.

"If the data is supportive and subject to regulatory consultation, Moderna may proceed with regulatory filings for children 2-5 years of age thereafter," the company said.

Moderna's vaccine, based on the messenger RNA platform, already has authorisations in Europe, UK, Australia, and Canada for adolescents aged 12-17 years, and has submitted applications for children in 6 to 11 years.

In the United States, the vaccine is authorized by Food and Drug Administration as primary two-dose regimen and booster dose for adults 18 years and older. The company, however, is yet to get an authorization from the regulator for use of its vaccine in children. REUTERS

Related topics

Covid-19 coronavirus vaccine Moderna children

Read more of the latest in

Advertisement

Popular

Advertisement

Stay in the know. Anytime. Anywhere.

Subscribe to get daily news updates, insights and must reads delivered straight to your inbox.

By clicking subscribe, I agree for my personal data to be used to send me TODAY newsletters, promotional offers and for research and analysis.

Aa